Pharmaceutical

Boehringer and 3T Biosciences partner to develop cancer immunotherapies

Boehringer Ingelheim has signed a deal with 3T Biosciences for the discovery and development of next-generation cancer immunotherapies.

Jan 5, 2024 - 18:00
Boehringer and 3T Biosciences partner to develop cancer immunotherapies
Boehringer Ingelheim has signed a deal with 3T Biosciences for the discovery and development of next-generation cancer immunotherapies.
Read the original article

Tags:

Previous Article

Rhythm expands obesity portfolio with Phase II weight loss drug for $100m

Next Article

Avistone raises $140m to support drug research and development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sens. Bernie Sanders, Bill Cassidy reach deal on PBM, generic reform

STAT+: Sens. Bernie Sanders, Bill Cassidy reach deal on...

Apr 25, 2023

STAT+: Tracking the FDA advisory panel on Sarepta’s gene therapy for Duchenne muscular dystrophy

STAT+: Tracking the FDA advisory panel on Sarepta’s gen...

May 13, 2023

FDA approves updated Covid vaccines

FDA approves updated Covid vaccines

Sep 12, 2023